Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease by Elizabeth M Wikler et al.
RESEARCH Open Access
Would you want to know? Public attitudes on
early diagnostic testing for Alzheimer’s disease
Elizabeth M Wikler1*, Robert J Blendon2 and John M Benson2
Abstract
Introduction: Research is underway to develop an early medical test for Alzheimer’s disease (AD).
Methods: To evaluate potential demand for such a test, we conducted a cross-sectional telephone survey of 2,678
randomly selected adults across the United States and four European countries.
Results: Most surveyed adults (67%) reported that they are “somewhat” or “very likely” to get an early medical test
if one becomes available in the future. Interest was higher among those worried about developing AD, those with
an immediate blood relative with AD, and those who have served as caregivers for AD patients. Older respondents
and those living in Spain and Poland also exhibited greater interest in testing. Knowing AD is a fatal condition did
not influence demand for testing, except among those with an immediate blood relative with the disease.
Conclusions: Potential demand for early medical testing for AD could be high. A predictive test could not only
advance medical research, it could transform political and legal landscapes by creating a large constituency of
asymptomatic, diagnosed adults.
Keywords: Alzheimer’s disease, medical testing, predictive testing, medical decision-making, public attitudes,
preclinical
Introduction
In 2011, an international team of experts revised the
diagnostic criteria and guidelines used to identify Alz-
heimer’s disease (AD). In recognition of recent scientific
discoveries, the group proposed a research agenda
focused on early detection of AD, particularly when the
disease is in a preclinical stage: after key biological
changes have started to occur in the brain, but before
the onset of noticeable symptoms [1]. Their hope was
that identifying the disease in this preclinical stage will
facilitate the development of new treatments to slow or
halt the progression of the disease [2]. Across the globe,
research on the predictive value of early medical tests
used to detect Alzheimer’s disease during this preclinical
phase is underway, and is showing promising results
[3,4].
Although nascent, efforts to create an early medical test
for Alzheimer’s disease using both genetic information
and disease biomarkers are gaining traction and, in the
future, may be available for broad populations of asymp-
tomatic patients outside of the research environment.
While this could result in tremendous breakthroughs
regarding treatment technologies, it raises practical, ethi-
cal and financial questions for individuals and commu-
nities across the globe. Most of all, people all over the
world will face a decision: should they get tested? Would
they want to know whether they will get this fatal,
untreatable disease?
This paper draws on public opinion data from four
Western European countries and the United States to
assess potential international demand for early diagnostic
testing for Alzheimer’s disease. We also explore some of
the factors associated with high and low levels of interest
in early medical testing for AD, employing constructs
from the Health Belief Model, a commonly used theoreti-
cal model that predicts utilization of health services [5].
Our results suggest that demand for Alzheimer’s testing
among asymptomatic patients could be high across all
five countries, particularly among those who perceive
themselves to be at high risk for the disease.
* Correspondence: bethwikler@post.harvard.edu
1Harvard Graduate School of Arts and Sciences, 14 Story Street, 4th Floor,
Cambridge, MA 02138 USA
Full list of author information is available at the end of the article
Wikler et al. Alzheimer’s Research & Therapy 2013, 5:43
http://alzres.com/content/5/5/43
© 2013 Wikler et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Early medical testing for AD
For decades, scientists have been working to develop a
reliable, predictive test for Alzheimer’s disease. In 1994,
genetic testing for late-onset Alzheimer’s disease became
available primarily in research settings, offering patients
a probabilistic measure of their risk for the disease by
analyzing their apolipoprotein E (ApoE) genotype. Indi-
viduals with two ApoE ε4 alleles have more than seven
times increased risk of developing AD than those with
the ApoE ε3 allele [6]. However, the ApoE ε4 allele is
neither a necessary nor sufficient predictor of the dis-
ease, and the association between ApoE ε4 allele and
AD has been shown to vary by race and ethnicity [7].
For these reasons and others - including the test’s low
sensitivity and specificity, the difficulty of interpreting
probabilistic results, and the lack of prevention options
- experts have largely opposed widespread clinical adop-
tion of this genetic test [8].
Other initiatives have focused on disease biomarkers -
particularly those measuring changes in amyloid beta
accumulation, synaptic and neuronal function, and brain
structure - in hopes of developing tests that can track
pathophysiological changes related to the development of
the disease [9-13]. If these new tests can more accurately
predict the onset of Alzheimer’s disease, it is feasible that
at some point in the future, they could be incorporated
into a broader set of tests used for the early detection
and diagnosis of Alzheimer’s disease and made available
to patients outside research settings.
Health belief model
In this paper, we drew on the Health Belief Model
(HBM) to develop our hypotheses about the social and
demographic factors that predict interest in AD testing.
The HBM is a theoretical framework developed by the
U.S. Public Health Service to help explain low participa-
tion rates in disease prevention programs [5,14,15]. The
core premise of the model is that health behaviors, such
as testing, are driven by personal beliefs about health
conditions, for example, the extent to which a person
feels threatened by a particular health condition, and
the costs and benefits of the strategies available for its
detection and treatment [14]. Individuals assess threat
based on their perceptions of how susceptible they are
to an illness and the severity of the illness, including its
impact on their future [16]. In this study, we expected
that measures of perceived risk would positively predict
interest in testing, whereas measures of disease severity,
including knowing the disease was fatal, would inversely
predict interest [17-19]. Previous work also suggests that
perceived benefits, such as enhanced planning and deci-
sion-making abilities around future care options, predict
interest in testing, whereas perceived costs, such as lack
of treatment, depress interest and uptake [20-22].
Methods
Survey data and study participants
The data for this paper come from an international tele-
phone survey with a randomly-selected sample of 2,678
adult respondents age 18 and older, drawn from five
countries: France, Germany, Poland, Spain and the Uni-
ted States. The Harvard School of Public Health and
Alzheimer Europe commissioned the survey to assess
public understanding about Alzheimer’s disease. The
fieldwork was conducted from 7 to 27 February 2011 by
TNS which is one of the largest, independent research
companies in the world and is based in London with
branches in each of the five countries surveyed. In each of
the five countries, interviews were conducted both by land-
line telephone using random-digit dialing and by cell phone
using numbers chosen randomly from a list of cell phone
numbers across the country. Interviews were conducted in
the language of each country. In the United States, inter-
views were conducted in both English and Spanish. The
average length of an interview was 12 minutes [23].
The survey, which has been described elsewhere,
focused on eight broad topics, ranging from levels of pub-
lic concern about the disease to public beliefs about
whether an effective treatment is available to slow the pro-
gression of the disease [23]. In this analysis, we focused on
results related to interest in future early diagnostic testing
for the disease, should such a test become available.
In December 2010, the Institutional Review Board at
the Harvard School of Public Health ruled that this
study was not human subject research (Protocol
#19950-101).
Informed consent was obtained in the following man-
ner. The interviewer told potential respondents that the
call was being made on behalf of the Harvard School of
Public Health. They were also told that the information
they provided would remain confidential and be used
for research purposes only. Potential respondents were
not pressured into responding, and could have chosen
not to be interviewed. Personal identifiers such as tele-
phone numbers were discarded.
Statistical analyses
Nonresponse in telephone surveys produces some
known biases in survey-derived estimates, because parti-
cipation tends to vary for different subgroups of the
population. To compensate for these biases, the sample
data were weighted to reflect the actual composition of
the adult population in the surveyed countries, calcu-
lated on the basis of census data from each country,
according to age, gender and region. The sample data
were also weighted by telephone status (landline, cell).
Other techniques, such a selection within households,
were used to help ensure that the sample in each coun-
try was representative.
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We used chi-squared tests (assessed at the conven-
tional alpha level of 0.05) to evaluate the association
between interest in testing and levels of perceived threat,
perceived costs and benefits, and social and demographic
factors. We then used regression analysis to analyze vari-
ables that predicted interest, adjusting for social and
demographic factors. Only the final models are shown.
As recommended by Strecher and Rosenstock, we did
not aggregate items measuring the constructs of the
health belief model, despite some measures being moder-
ately interrelated, and instead, evaluated the impact of
each measure separately [24]. However, we tested for
potential interactions among these variables. As robust-
ness checks, we ran country-specific regression models,
and evaluated all models using probit regression.
Our main outcome variable - interest in testing - was
derived from the following survey question: “[i]n the
future, a medical test might become available that would
tell people before they had symptoms whether they will
get Alzheimer’s disease in the future. If such a test became
available, how likely do you think it is that you would get
the test - very likely, somewhat likely, not too likely, or not
at all likely?” Because studies of genetic testing for other
diseases have found that actual take-up rates tend to be
lower than rates of expressed interest once tests become
available, we focused our analyses on respondents who
reported that they are “very likely” to get tested (1, very
likely; 0, somewhat/not too/not at all likely) [21]. In addi-
tional analyses, we evaluated predictors of being “not at all
likely” to get tested, creating a separate dichotomous out-
come variable (1, not at all likely; 0, very likely/somewhat/
not too). We dropped the “Don’t know/Refused” respon-
dents (n = 53) from this analysis.
The independent variables in this analysis were drawn
from the Health Belief model [5,14]. Measures were bro-
ken into categories that evaluate levels of perceived threat
and perceived costs and benefits of testing; demographic
and psychological variables were also included in the mod-
els. Given differences in educational systems across the
countries, we divided respondents into three categories:
low, middle and high educational attainment. Across all
countries, low education captured respondents who com-
pleted primary and some secondary schooling; middle
education captured respondents who had completed high
school and potentially some college; and high education
referred to respondents with a college or post-university
degree. Race and ethnicity data were collected only in the
United States, so models evaluating their impact were con-
ducted only for respondents living in that country.
Respondents were broken down into the following cate-
gories: white (non-Hispanic), black (non-Hispanic), Hispa-
nic, other (non-Hispanic). The other racial category
included respondents who identified as Asian, Pacific
Islander, Native American or other.
Reference categories for dichotomous variables were
set at zero, and for categorical variables, they were set as
the first group. All analyses were conducted using Stata
11 software, which was generated by StataCorp LP, a
company located in College Station, Texas in the United
States.
Results
Table 1 shows unadjusted, weighted statistics on the
relationship between interest in testing and our inde-
pendent variables for respondents who expressed they
would be “very likely” to take a medical test for AD.
Bivariate analyses
Overall, we found that more than two-thirds of respon-
dents across all countries would be “very likely” (30%) or
“somewhat likely” (37%) to obtain an early medical test if
it were available in the future; 21.1% would be “not too
likely,” and 11.9% would be “not at all likely” to pursue
testing. Individuals who reported high levels of perceived
threat, across a range of measures, were more likely to
indicate that they are “very likely” to undergo testing
[15,17,25,26]. For example, we found that 35.3% of
respondents who had an immediate blood relative with
AD report that they were “very likely” to get tested as
compared to 27.8% without an affected relative. Similar
patterns emerged for those who served as a caretaker or
decision-maker (40.4% versus 27.9%), for those who were
“very” or “somewhat” worried about getting AD (38.1%
versus 23.5%), and for those who were in “fair” or “poor”
health (34% versus 28.9%). Unexpectedly, knowing that
AD is a fatal condition - a measure of perceived disease
severity - had no statistically significant relationship to
interest in testing.
Only one of our measures of perceived costs and bene-
fits was associated with interest in testing: those who
expected to rely on a paid caregiver if they developed
AD, as opposed to a spouse, child, friend or other, were
more likely to desire testing (33.4% versus 28.6%).
Our analysis showed that all of the demographic and
psychological control variables in our model were statisti-
cally significantly related to being “very likely” to pursue
testing. Older populations - those aged 50 and above -
reported more often than younger populations that they
were “very likely” to get an early AD test (for example,
38.9% for 65 to 74 year olds versus 25.3% for 18 to 29
year olds); women were more interested than men (32.2%
versus 27.7%); and those with the lowest levels of educa-
tion were more interested than those with the highest
(32.4% versus 25.9%). Country-level differences were also
particularly striking - Spain and Poland had the highest
shares of respondents reporting that they were “very
likely” to pursue testing (39.6% and 30.5%) and Germany
the lowest (23.6%).
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Table 1 Characteristics of total sample and subpopulations who are “very likely” to obtain preclinical AD test
Entire sample Very likely to get early medical test for AD
Entire sample 30.0% [28.1 to 31.9]
Have/had immediate blood relative with AD
No 77.1% [75.2 to 79.0] 27.8%*** [25.7 to 30.1]
Yes 22.9% [21.0 to 24.8] 35.3% [31.2 to 39.7]
Served as decision-maker or caretaker for AD patient
No 83.0% [81.4 to 84.7] 27.9%* [25.8 to 30.0]
Yes 17.0% [15.3 to 18.6] 40.4% [35.6 to 45.5]
Worried will get Alzheimer’s disease
Not too/not at all/don’t know/refused 55.3% [53.1 to 57.5] 23.5%** [21.2 to 26.0]
Very/somewhat worried 44.7% [42.5 to 46.9] 38.1% [35.1 to 41.2]
Health status
Fair/poor 20.3% [18.5 to 22.2] 34%* [29.8 to 38.4]
Excellent/very good/good 79.7% [77.8 to 81.5] 28.9% [26.8 to 31.1]
Think AD is fatal
No/Don’t know/refused 55.5% [53.3 to 57.7] 28.9% [26.4 to 31.5]
Yes 44.5% [42.3 to 46.7] 31.4% [28.6 to 34.4]
Marital status
No 46.3% [44.1 to 48.6] 28.9% [26.1 to 31.9]
Yes 53.7% [51.4 to 55.9] 30.9% [28.4 to 33.6]
Expect paid caregiver to be primary caretaker if develop AD
No 70.8% [68.7 to 72.8] 28.6%* [26.3 to 30.9]
Yes 29.2% [27.2 to 31.3] 33.4% [29.8 to 37.2]
Believe an effective AD treatment is available now or will be in five years
No/don’t know/refused 32.1% [30.0 to 34.2] 28.5% [25.3 to 32.0]
Yes 67.9% [65.8 to 70.0] 30.8% [28.4 to 33.2]
Age
18 to 29 23.7% [21.7 to 25.8] 25.3%** [21.3 to 29.9]
30 to 49 37.2% [35.1 to 39.4] 25.1% [22.2 to 28.2]
50 to 64 21.6% [19.9 to 23.3] 36.9% [33.1 to 40.9]
65 to 74 11.6% [10.2 to 13.0] 38.9% [33.2 to 45.0]
75 to 85+ 5.9% [4.9 to 6.9] 34.3% [27.0 to 42.3]
Gender
Male 48.2% [46.0 to 50.5] 27.7%* [24.9 to 30.5]
Female 51.8% [49.5 to 54.0] 32.2% [29.6 to 34.9]
Educational attainment
Low 32.5% [30.4 to 34.6] 32.4%* [29.0 to 35.9]
Middle 30.2% [28.1 to 32.3] 32.1% [28.6 to 35.9]
High 37.3% [35.1 to 39.5] 25.9% [23.0 to 29.0]
Country
France 20.8% [19.0 to 22.6] 26.8%*** [22.9 to 31.2]
Germany 17.9% [16.2 to 19.7] 23.6% [19.7 to 28.0]
Poland 17.8% [16.1 to 19.5] 30.5% [26.2 to 35.2]
Spain 18.4% [16.6 to 20.1] 39.6% [34.9 to 44.4]
United States 25.1% [23.1 to 27.0] 29.7% [26.0 to 33.7]
Race (U.S. Only, N = 639)
White 68.3% [64.3 to 72.4] 25.3% [21.1 to 30.0]
Black 11.6% [9.1 to 13.9] 45.1% [34.6 to 56.0]
Hispanic 14.1% [11.3 to 16.9] 34.7% [25.7 to 44.8]
Other (Asian, Pacific Islander, Native American, Other) 6.1% [3.1 to 8.9] 39.1% [18.1 to 65.2]
Would see doctor if showing symptoms of AD
No 9.2% [7.8 to 10.5] 19%** [13.3 to 26.6]
Yes 90.8% [89.5 to 92.2] 31.4% [29.4 to 33.5]
N = 2,678; *P < .05; **P < .01; ***P < .001 using chi-square tests of differences between expected and observed distributions. Sample sizes vary across categories
due to missing data. Confidence intervals in brackets.
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Lastly, we found that those with potentially stronger
coping abilities, as captured by their more active infor-
mation-seeking style (measured by asking respondents if
they would see a doctor if showing symptoms of AD)
were more likely to express interest in testing (31.4%
versus 19%) [27].
In the United States, whites were less likely than
blacks and Hispanics to respond that they would be
“very likely” to get an early medical test for AD (25.3%
compared to 45.1% and 34.6%, respectively). However,
only the difference between whites and blacks was sta-
tistically significant.
We tested variables associated with being “not at all
likely” to get an early medical test, and found that
results largely mirrored those outlined above with one
additional finding: those who believed there was a treat-
ment for AD, or that one will become available in the
next five years, were less likely to respond that they
were “not at all likely” to get tested (10.5% versus
14.1%). This suggested that while treatment optimism
may not motivate people to express strong interest in
testing, it did prevent people from ruling out testing
altogether.
Nevertheless, measures of perceived risk and perceived
costs and benefits were interrelated. For example,
women and caretakers were more likely to report being
worried about getting AD, and having a close blood
relative with AD was positively associated with higher
levels of treatment optimism. To disentangle these
effects, we used multivariate logistic regression to adjust
for these correlations and check for potential interactive
effects.
Regression results
Our logistic regression models evaluated interest in test-
ing, adjusting for measures of perceived risk, measures
of perceived costs and benefits, and demographic and
social controls. Table 2 displays our results. On average,
after controlling for social and demographic factors, we
find that 28.4% of survey respondents are “very likely”
to get a hypothetical, early medical test for AD.
Although several factors, including the cost of the test
and methods of test administration, may reduce rates of
actual take-up once and if an AD test is available, this
level of interest is similar to the 25% take-up rates docu-
mented among first-degree relatives of AD patients who
were part of disease registries and contacted to partake
in a randomized clinical trial for a genetic testing for
AD [28].
Measures of perceived risk were the strongest predic-
tors of interest in testing. For example, holding all else
constant, the odds of being “very likely” to pursue test-
ing were 76% higher for those worried about developing
AD than for those not worried. Expecting to rely on a
paid caregiver, older age, and country of residence also
remained positive, statistically significant predictors of
being interested in early medical testing.
On its own, knowing the disease is fatal had no statis-
tically significant effect on interest in testing (OR =
1.112, P >0.05). However, among those who knew the
disease is fatal, the predicted probability of expressing
interest in testing was higher for those who have a
blood relative with AD as opposed to those without
(38.7% versus 26.8%). Moreover, although poor health
status was predictive of interest in testing in bivariate
analyses, it was the worried well who expressed higher
levels of interest in our final model. Among those who
were worried about AD, those in better health were
more likely than those in worse health to desire testing
(predicted probabilities of 36.3% versus 31.9%).
These results varied little when we broke them down
by country (Table 3). Caretakers, especially those in
Poland, report higher interest in testing as opposed to
those who have not served as a caretaker or decision-
maker for an AD patient (OR = 2.717, P < 0.001).
Despite different social support systems, interest was
also high in most countries among those who expected
to rely on a paid caregiver. However, although marital
status was not a significant predictor of testing in the
aggregate, married respondents in the United States
were less likely than single respondents to report a
desire for the test (OR = 0.641, P < 0.05).
Table 4 shows that in the United States, race and eth-
nicity were also significant predictors of interest in AD
testing. On average, blacks and Hispanics were more
likely than whites to report an interest in testing. The
predicted probability of pursuing an early medical test
for AD for whites was 23.1%, but it was nearly double
that for blacks (41.3%) and 35.3% for Hispanics. There
were no significant differences between minority groups
on rates of interest.
Lastly, we explored factors associated with being “not
at all likely” to pursue early medical testing. Not surpris-
ingly, having a positive information-seeking style, for
example, respondent reporting that s/he would visit a
physician if exhibiting symptoms of Alzheimer’s, was
inversely related to being “not at all” interested in test-
ing (OR = 0.534, P < 0.01). This suggests that those
who would avoid physician visits were also more likely
to avoid early medical testing.
Discussion
This is the first large, international, randomized survey
of public interest in potential early medical testing for
AD. We find that two out of three respondents would
be interested in obtaining a hypothetical early medical
test for AD. These rates are similar to results found in a
2011 internet survey conducted in the United States
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finding high levels of interest in and willingness to pay
for AD testing (between 70% and 74.8% of respondents)
[29]. In a study of first-degree relatives who had under-
gone APOE susceptibility testing, fear of developing the
disease and a desire for information were among the
chief predictors of willingness-to-pay [30].
These results suggest that demand will be highest
among those who perceive themselves to be at risk for
the disease, including those with a family history of AD,
those worried about getting the disease, and those who
serve as caregivers or decision-makers for AD patients
[17,19,25,26]. Our study adds to the literature by
uniquely showing the interactive nature of these mea-
sures. While in our bivariate analyses, those in worse
health were more likely than healthy populations to
desire testing, it was the worried well who expressed
higher levels of interest in a hypothetical predictive test,
controlling for demographic and social factors. While
our own study does not directly ask about motivation
for test-taking, studies of other late-onset disorders find
that those with high levels of perceived risk view testing
as a way of practically and emotionally coping with their
worry, gaining control and getting clarity about their
future [15,31]. Even in circumstances where no treat-
ment options were available, study participants high-
lighted the non-medical benefits to test information,
highlighting the “value of knowing” and the opportunity
to change behaviors, such as getting follow-up care,
spending time with family, and arranging their personal
finances [16,29].
Previous work on these survey data found that aware-
ness of the disease’s fatality was limited, ranging from
33% in Germany to 61% in the United States; however,
awareness was higher among blood relatives of AD
patients in France, Poland and Spain [23]. We hypothe-
sized that interest in testing would be lower among
Table 2 Logistic Regression results evaluating variables predictive of being “very likely” to obtain preclinical AD test
Model 1 Model 2
Variables AOR AOR
Measures of perceived threat
Respondent is or was decision-maker or caretaker for AD patient 1.306* 1.330*
Worried will get Alzheimer’s 1.760*** 1.22
“Excellent/Good/Very Good” Health Status 0.972 0.763
Worried* Excellent/Good/Very Good Health Status – 1.610*
Have/had immediate blood relative with AD 1.312* 0.971
Think AD is fatal 1.112 0.96
Immediate blood relative* Think AD is fatal – 1.783*
Measures of perceived costs and benefits
Marital status of respondent 0.963 0.977
Expect paid caregiver to be primary caretaker if develop AD 1.277* 1.291*
Believe an effective AD treatment is available now or will be in five years 1.064 1.051
Demographic controls
Age of respondent
30 to 49 1.019 1.019
50 to 64 1.573** 1.582**
65 to 74 1.702** 1.733**
75 to 85+ 1.465 1.489
Female 1.18 1.178
Educational Attainment
Middle education 1.112 1.105





United States 1.208 1.206
Measure of Psychological Status
Would see doctor if showing symptoms of AD 1.44 1.416
AOR = Adjusted odds ratio; reference groups, in order of the categories displayed in the table are: Ages 18 to 29; Low Education; France; * P < 0.05,** P < 0.01,
*** P < 0.001.
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those who knew the disease was fatal, and even more so
among those who genetically had higher chances of
developing the disease. Unexpectedly, this knowledge
had no significant effect on interest, except, inversely so,
among respondents with a blood relative with AD. As
noted previously, these respondents may value informa-
tion over uncertainty, even in the context of potentially
negative results [29].
Table 3 Country-level logistic regression results evaluating variables predictive of being “very likely” to obtain test
Variable Entire
sample
France Germany Poland Spain United
States
Measures of perceived threat
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United States 1.208 (0.192)
Measure of Psychological Status








Observations 2357 494 423 419 436 585
Wald test 110.47 33.44 23.48 50.6 21.13 34.21
P-value 0 0.007 0.102 0 0.174 0.005
+P < 0.10,* P < 0.05,** P < 0.01, *** P < 0.001. Table displays adjusted odds ratios and standard errors in parentheses. Country-level sample sizes are reduced due
to missing data. Reference groups, in order of the categories displayed in the table are: Ages 18 to 29; Low Education; France
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Nevertheless, it could be that rates of interest do not
translate into rates of take-up once, and if, a definitive,
predictive test becomes available in clinical settings [27].
Yet, we anticipate that high prevlance rates for AD,
coupled with its later age of onset and broader media pre-
sence, could bolster participation rates beyond those docu-
mented for other uncurable, untreatable conditions
[27,28].
Middle- to older-age populations who are both closer
to the age of onset and more likely to serve as caretakers
are also more likely to express interest in testing [28].
Looking forward, as global populations age and as more
people gain experience with the disease, the demand for
early medical AD testing could rise. We anticipate that
this demand will vary by country, with potentially high
levels of demand in Poland, where support systems for
AD patients are more fragmented and thus planning for
care falls to individuals, and Spain, where AD related
media has been prevalent and informal care giving is
more common [32]. Compounding these factors, we
expect interest and utilization of early medical testing for
AD across countries to be affected by variations in clini-
cal practice, care resources, cultural norms, disease epi-
demiology, levels of disease awareness and public policy
responses [33,34].
Lastly, compared to whites, blacks and Hispanics living
in the United States expressed significantly more interest
in predictive testing for AD. This was unexpected given
that earlier studies of genetic testing for cystic fibrosis,
hereditary breast and ovarian cancers, and Alzheimer’s dis-
ease, found either no differences across racial groups or
that whites were more likely to express interest in genetic
testing, seek out genetic counseling, and undergo testing
once available [18,35-38]. However, one national tele-
phone survey conducted in 2000 found that African-
American and Latino adults, in comparison to whites,
were more likely to express interest in genetic testing for
untreatable conditions [39].
Previous surveys have found that African American
and Hispanic populations had higher levels of treatment
optimism, believing scientists were close to finding a
cure and that a cure would be available during the study
participant’s lifetime; moreover, minorities were also
more likely than whites to report lower levels of concern
about developing AD, which could explain differences
observed in our study [35,40,41]. However, we found no
statistically significant differences across racial groups
on our survey measures of treatment optimism or levels
of perceived risk. More work is needed to understand
how these beliefs and interest vary across racial groups,
and the extent to which individual- and structural-level
factors affect rates of take-up once and if testing
becomes available [39,42,43].
Transforming medical and legal landscapes
If an early diagnostic test is indeed developed and demand
matches global interest, millions of people in each of the
studied countries will become members of a new popula-
tion and political advocacy group: asymptomatic adults liv-
ing with a diagnosis of Alzheimer’s disease. Consequently,
policymakers and clinicians should expect significant
changes in the utilization of medical and economic
resources and address potential legal obstacles.
In the medical realm, diagnosed but asymptomatic
individuals are likely to press for follow-up testing,
ongoing medical monitoring, and medical management
of potential complications associated with Alzheimer’s
disease [44]. Given the uncertainty around the disease’s
pathogenesis and treatment mechanisms, the clinical
value of such tests is unclear, and these additional costs
could strain already-overburdened health systems, mak-
ing the tradeoffs involved in allocating medical resources
even more difficult [32,45]. However, the non-clinical
benefits of testing, such as signing advanced directives
and spending more time with family and friends, do pro-
vide value and should be appropriately considered in
cost-benefit calculations [46].
In the legal realm, early medical testing for AD raises
challenging questions related to testing protocols, disclo-
sure practices, confidentiality protections, employment
and insurance discrimination, and the availability of fol-
low-up care [47,48]. If not appropriately addressed, any of
these issues could pose real barriers to test participation.
For instance, insurers, including health, life, disability or
Table 4 Logistic regression results evaluating interest in preclinical AD test by race in the United States
Variable US Predicted probability
Race
White 1.000 (–) 23.1%
African American 2.391** (0.689) 41.8%
Hispanic 1.820* (0.499) 35.4%
Other (Asian, Native American, or Other) 2.259 (1.297) 40.5%
Observations 585
+P < 0.10,* P < 0.05,** P < 0.01, *** P < 0.001. Table displays adjusted odds ratios and standard errors in parentheses. White is the reference category. Sample
size is reduced due to missing data. Model controls for measures of perceived threat, perceived costs and benefits, demographic controls, and measure of
psychological status.
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long-term care insurers, may want access to private health
information to protect against adverse selection. These
desires are not unreasonable. In the United States, one
study found that individuals who underwent genetic test-
ing for Alzheimer’s disease were five times more likely
than those who were untested to change their long-term
care insurance coverage in the year following testing [49].
Similar results were found among those who were found
to be at risk for Huntington’s disease [50].
The US and Europe have enacted a range of measures
to protect individuals against employment and insurance
discrimination on the basis of genetic information, such
as the Genetic Information and Nondiscrimination Act
of 2008 in the US and the 1999 Oviedo Convention of
Human Rights and Biomedicine in Europe. However,
research suggests that the laws protecting against
genetic discrimination in Europe have had mixed results
on providing adequate protections and have not always
kept pace with scientific advancements [51].
Furthermore, if an early medical test were developed
for Alzheimer’s disease that did not involve genetic
information, such as blood tests evaluating protein
levels, it is unclear to what extent these anti-discrimina-
tion protections would apply to diagnosed individuals.
Before introducing early medical testing for AD into
clinical practice, government leaders will need to exam-
ine whether existing protections are sufficient for diag-
nosed individuals and how these protections affect the
viability of voluntary private insurance markets.
Limitations and opportunities for future work
Future research could build on this analysis in a number
of ways. First, imprecision in our survey question may
introduce some bias in our results. For example, the
phrase “in the future” is used twice: to describe both the
potential existence of an early medical test for Alzheimer’s,
and to refer to the possibility that the respondent will get
Alzheimer’s disease later in life. Our results encapsulate
respondents’ beliefs about the timing and availability of
such a test, their interest in the actual test, and their level
of concern for events that may happen in the future.
Although we control for beliefs about scientific advance-
ment, levels of concern about getting Alzheimer’s disease,
and age in our models predicting interest, future surveys
should consider introducing a hypothetical situation in
which a test already exists.
Second, we do not include potentially relevant finan-
cial, social and emotional variables, such as the respon-
dents’ insurance status, willingness to pay for testing,
test administration, family size, country-specific policies,
AD media coverage, level of religiosity, history of
depression or fear of discrimination [30,35,46,52,53].
Third, future surveys should measure whether people
would want to take such a test if they were told that no
treatment or cure is currently available. Fourth, while
we implied that the test would be completely predictive,
we did not explicitly state so. As has been done pre-
viously, future work could test whether respondents
would want to take a test if it were partially or perfectly
predictive [25,46]. Lastly, future analyses could enhance
this work by including more questions about test moti-
vations, perceived costs and benefits, and measures of
psychological style, including the Miller Behavioral Style
Scale [22,54,55].
Conclusions
In summary, our survey indicates that across four
European countries and the United States, interest in
early medical testing for Alzheimer’s disease is high. We
expect those with high levels of perceived risk - those
who are worried about getting AD as well as those with
more experience with the disease, including caregivers
and blood relatives of AD patients - will be among
those most likely to pursue testing once it becomes
available. While early detection could hasten the devel-
opment of treatment protocols, high demand for testing
and the creation of a large group of asymptomatic adults
with an Alzheimer’s diagnosis could have significant
political, economic and legal implications, and could
transform the way AD is addressed by countries in the
future.
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